Notice of Intent to Publish a Funding Opportunity Announcement for ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center
ID: 353689Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $800K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353689
Timeline
  1. 1
    Forecast Posted Apr 26, 2024 12:00 AM
  2. 2
    Forecast Due Jul 26, 2024 12:00 AM
  3. 3
    Posted Apr 22, 2024 12:00 AM
  4. 4
    Due Not available
Description

The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center. The MAGen Consortium aims to develop Machine Learning (ML) and Artificial Intelligence (AI) tools to improve the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The Coordinating Center (CC) will be responsible for coordinating diverse teams, facilitating collaborative research activities, and disseminating developed resources. The funding opportunity is expected to be released in Spring 2024, with an application due date in Summer 2024. The estimated award ceiling is $800,000, and one award is expected to be granted.

Point(s) of Contact
No information provided.
Files
No associated files provided.
Similar Opportunities
ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed)". This grant aims to solicit applications for the Coordinating Center (CC) of the MAGen Consortium, which focuses on developing Machine Learning (ML) and Artificial Intelligence (AI) tools to enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The CC will be responsible for coordinating technical, scientific, and administrative activities to support the research efforts of the Consortium. This includes developing consortium-wide plans, coordinating ML/AI tool development and cross-validation, and disseminating the developed resources. The grant does not require cost sharing or matching and falls under the category of Health. The deadline for applications is July 28, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-005.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-005.html).
Notice of Intent to Publish a Funding Opportunity Announcement for ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites. This opportunity aims to explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The objective is to collaboratively identify both genomic and non-genomic factors influencing disease development in individuals carrying pathogenic genetic variants within a research consortium. The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross-validated in genomic translational research settings to ensure their robustness and generalizability. The consortium will also address the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine. The funding opportunity is expected to be published in Spring 2024, with an application due date in Summer 2024.
ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed)". This grant aims to establish a research Consortium, MAGen, to collaboratively explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The primary goal of this grant is to identify both genomic and non-genomic factors influencing disease development in individuals carrying pathogenic genetic variants. The ML/AI tools developed through this grant will leverage existing multimodal genomic and non-genomic data and will be cross-validated in genomic translational research settings to ensure their accuracy and generalizability for translational purposes. In addition to the development of ML/AI tools, the Consortium will also focus on exploring the ethical, legal, and social implications (ELSI) of integrating these tools into genomic medicine. This will involve the establishment of an ELSI Framework for their development and the implementation of ELSI research projects. The grant is a Cooperative Agreement and falls under the category of Health. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant has a closing date of July 28, 2024, and an award ceiling of $1,600,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-004.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-004.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC). This center will play a crucial role in the second phase of the Somatic Cell Genome Editing (SCGE) program, which aims to accelerate the development of genome editing therapeutic agents. The TCDC will focus on coordinating and disseminating successful strategies for initiating first in human clinical trials using genome editing therapeutics. This initiative is part of a larger consortium that will optimize promising clinical candidates towards Investigational New Drug (IND) filings and first in human clinical trials. The funding opportunity is expected to be published in Spring 2022, with application due dates in Summer 2022.
Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the creation of a Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A. This initiative aims to establish a Clinical Coordinating Center that will coordinate and support research on Factor VIII immunogenicity in severe Hemophilia A. The Clinical Coordinating Center will be responsible for managing and overseeing the project, ensuring that milestones are met, and facilitating collaboration among researchers. The FOA will provide funding for a three-year milestone-driven UG3 award, with the potential for up to four additional years of funding based on successful milestone completion. The Clinical Coordinating Center will work in parallel with a Biospecimen and Data Resource Center, which will provide data management and laboratory support for the initiative. The FOA is expected to be released in the near future, allowing potential applicants to prepare competitive and responsive scientific projects.